Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03543826 · ClinicalTrials.gov registry record · Phase 4
Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex
A Phase 4 study of Muscle Weakness, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 201
- Enrollment target
- 1
- Study location
NCT03543826: Completed Phase 4 study of Muscle Weakness, sponsored by University of Washington.
NCT03543826 is a Phase 4 study of Muscle Weakness that has completed, run by University of Washington. The registered enrollment target is 201 participants, above the 67-participant average among 25 other Muscle Weakness trials with a reported enrollment target (200% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03543826, a Phase 4 study of Muscle Weakness, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 201 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an estimation study, prospectively evaluating the incidence of postoperative residual neuromuscular blockade (PRNB) when a best practice protocol is implemented for a cohort of abdominal surgery and orthopedic surgery patients. The protocol is developed within the constraint of subjective monitoring, quantitative monitoring is not used, and use of rocuronium for paralysis and either neostigmine or sugammadex for reversal. The primary outcome is the incidence of PRNB on arrival to the post-anesthesia care unit, defined as a train-of-four ration \<0.9.
Primary Outcome
Postoperative residual neuromuscular blockade is measured by a Train-of-four ratio \<0.9 as measured by acceleromyography.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Protocol for rocuronium neuromuscular block
Study Locations (1)
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2018-11-26 |
| Phase | Phase 4 |
What the finished NCT03543826 record still lists
NCT03543826 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 67-participant average among 25 other Muscle Weakness trials with a reported enrollment target (200% higher).
The record links to 1 condition, with Muscle Weakness appearing as the primary indexed condition, and to 1 intervention - of which Protocol for rocuronium neuromuscular block is the first listed.
NCT03543826 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03543826 about?
NCT03543826 is a clinical study titled "Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex". This is an estimation study, prospectively evaluating the incidence of postoperative residual neuromuscular blockade (PRNB) when a best practice protocol is implemented for a cohort of abdominal surgery and orthopedic surgery patients. The protocol is developed within the constraint of subjective mo...
What is the current status of trial NCT03543826?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 201 participants. The study started on 2018-05-21. Estimated completion is 2018-11-26.
What conditions does trial NCT03543826 study?
This clinical trial studies the following conditions: Muscle Weakness.
What interventions are being tested in trial NCT03543826?
The interventions under investigation include: Protocol for rocuronium neuromuscular block (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03543826?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03543826 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Weakness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03543826's enrollment target sits among peer trials
201 3rd of 25 higher than 23 of 25 other Muscle Weakness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle Weakness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depo-Medrol on Psoas After LLIF
RECRUITING · Phase 4
-
Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly
COMPLETED · Phase 4
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
RECRUITING
-
FIT Exercise in 30d of ULLS-induced Muscle Disuse
RECRUITING · NA
-
Muscle Recovery After Critical Illness
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI